```html

Yttrium‑90 Induced Radiation Hepatitis

Overview

Yttrium‑90 induced radiation hepatitis is an inflammatory liver condition that occurs after a patient receives Yttrium‑90 (Y‑90) radio‑embolization, a form of internal radiation therapy used primarily for primary or metastatic liver cancers. The Y‑90 microspheres lodge in the tumor’s vasculature and emit beta‑radiation that destroys cancer cells. When radiation reaches surrounding healthy liver tissue, it can provoke hepatitis—a spectrum ranging from mild biochemical liver‑enzyme elevation to clinically significant liver dysfunction.

Who it affects: The condition is seen almost exclusively in adults ≥18 years undergoing Y‑90 radio‑embolization for hepatocellular carcinoma (HCC), cholangiocarcinoma, or metastatic colorectal cancer to the liver. Although most patients tolerate the procedure well, those with pre‑existing liver disease (e.g., cirrhosis, chronic hepatitis B or C) are at higher risk.

Prevalence: Large registries report post‑radio‑embolization hepatitis in 10‑30 % of treated patients, with clinically significant hepatitis (grade ≥ 2 according to CTCAE) occurring in 5‑12 %.<sup>[1][2]</sup> Mortality directly attributable to radiation hepatitis is low (<1 %) but the condition can exacerbate underlying liver failure and affect overall survival.

Symptoms

Symptoms usually appear 1–8 weeks after Y‑90 treatment, though delayed presentations up to 3 months are reported. The severity correlates with the delivered radiation dose and baseline liver reserve.

• Fatigue or malaise – a vague sense of weakness, often the first clue.
• Right‑upper‑quadrant (RUQ) discomfort – dull ache or pressure behind the ribs.
• Jaundice – yellowing of the skin and eyes, indicating bilirubin rise.
• Pruritus (itching) – secondary to bile‑salt accumulation.
• Dark urine & pale stools – classic cholestatic pattern.
• Nausea or loss of appetite – may accompany RUQ pain.
• Ascites – accumulation of fluid in the abdomen, especially in patients with cirrhosis.
• Enlarged liver (hepatomegaly) – detectable on physical exam.
• Elevated liver enzymes – laboratory finding rather than a symptom, but often prompts work‑up.

Causes and Risk Factors

Primary cause

Y‑90 radio‑embolization delivers high‑energy beta particles (maximum energy 2.28 MeV) that travel a mean distance of 2.5 mm in tissue. While designed to concentrate within tumor vasculature, a portion of microspheres or scattered radiation inevitably irradiates adjacent normal hepatocytes, triggering inflammatory cascades, oxidative stress, and apoptosis – the pathophysiologic basis of radiation hepatitis.

Risk factors

• Pre‑existing liver disease – cirrhosis (any etiology), chronic hepatitis B or C, non‑alcoholic steatohepatitis (NASH). These livers have reduced regenerative capacity.
• High liver‑to‑lung shunt fraction – measured on technetium‑99m macro‑aggregated albumin (MAA) scan; shunts >20 % increase extra‑hepatic radiation and limit safe Y‑90 dose.
• Large tumor burden – >50 % of liver volume occupied by tumor requires higher Y‑90 activity.
• Elevated baseline bilirubin or International Normalized Ratio (INR) – indicates limited functional reserve.
• Previous liver‑directed therapies – prior trans‑arterial chemo‑embolization (TACE) or external beam radiation may compound injury.
• Age & comorbidities – older age, diabetes, or cardiovascular disease modestly increase susceptibility.

Diagnosis

Diagnosis is clinical, supported by imaging and laboratory data, and requires exclusion of alternative causes (e.g., viral hepatitis flare, biliary obstruction, drug‑induced liver injury).

Laboratory tests

• Liver enzymes – Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) often rise 2‑10 × upper limit of normal (ULN) within weeks.
• Alkaline phosphatase (ALP) & Gamma‑glutamyl transferase (GGT) – may increase in cholestatic patterns.
• Bilirubin – total bilirubin >2 mg/dL signals clinically significant hepatitis.
• Coagulation profile – INR elevation reflects synthetic dysfunction.
• Complete blood count – to rule out infection or hemolysis.

Imaging

• Contrast‑enhanced CT or MRI – may show peri‑tumoral low‑attenuation zones, hepatic edema, or new focal lesions differentiating from tumor progression.
• 99mTc‑MAA lung shunt scan – performed before therapy; a high shunt ratio predicts higher risk.
• Ultrasound with elastography – helps assess baseline fibrosis, which influences prognosis.

Other assessments

• Liver function scoring – Child‑Pugh, MELD (Model for End‑Stage Liver Disease) scores guide severity grading.
• Biopsy (rarely needed) – histology shows radiation‑induced necrosis, sinusoidal congestion, and inflammatory infiltrates; reserved for ambiguous cases.

Treatment Options

General principles

Management is largely supportive, aimed at minimizing further injury, promoting regeneration, and treating symptoms. No specific antidote exists for radiation‑induced injury.

Medications

• Corticosteroids – short courses (e.g., prednisone 0.5–1 mg/kg for 5–7 days) can reduce inflammation in moderate‑to‑severe cases; data are extrapolated from radiation‑induced pneumonitis and limited liver series.<sup>[3]</sup>
• Ursodeoxycholic acid (UDCA) – 13‑15 mg/kg/day improves cholestasis and may protect hepatocytes.
• N‑acetylcysteine (NAC) – antioxidant properties; given intravenously (150 mg/kg over 1 h, then 50 mg/kg over 4 h, then 100 mg/kg over 16 h) in cases with acute liver failure.
• Diuretics (e.g., spironolactone, furosemide) – for ascites management; monitor electrolytes.
• Pruritus control – antihistamines, cholestyramine, or rifampin in refractory itching.
• Analgesics – acetaminophen <10 mg/kg/day is safe; avoid NSAIDs if coagulopathy or renal dysfunction is present.

Procedural interventions

• Therapeutic paracentesis – for tense ascites causing respiratory compromise.
• Transjugular intrahepatic portosystemic shunt (TIPS) – considered in refractory portal hypertension after ruling out contraindications.
• Liver transplantation – last‑resort for irreversible liver failure in select candidates; rare due to limited donor availability and cancer recurrence risk.

Lifestyle and supportive measures

• Nutrition – high‑protein (1.2‑1.5 g/kg), calorie‑dense diet; supplement with branched‑chain amino acids if encephalopathy risk.
• Alcohol abstinence – eliminates a major hepatotoxin.
• Vaccinations – hepatitis A & B, pneumococcal, and annual influenza to prevent superimposed infections.
• Hydration – maintain euvolemia; avoid excessive fluid overload.

Living with Yttrium‑90 Induced Radiation Hepatitis

Daily management tips

• Monitor symptoms – keep a daily log of fatigue, abdominal pain, urine color, and stool appearance.
• Regular labs – schedule blood work (LFTs, INR, CBC) every 1–2 weeks for the first two months, then monthly as stable.
• Weight surveillance – sudden weight gain may signal fluid accumulation; report to your provider.
• Low‑sodium diet – ≤2 g sodium/day to reduce ascites risk.
• Physical activity – gentle walking or yoga improves circulation and mood without stressing the liver.
• Medication adherence – take prescribed steroids or UDCA exactly as directed; do not self‑adjust doses.
• Psychological support – coping with cancer treatment and liver issues can be stressful; consider counseling or support groups.

Follow‑up schedule

After Y‑90 therapy, most centers schedule a 4‑week post‑procedure visit, then at 8 weeks, 3 months, and every 3–6 months thereafter. Imaging (contrast‑enhanced MRI/CT) is usually performed at 1‑month and 3‑months to evaluate tumor response and rule out progressive liver injury.

Prevention

• Pre‑procedure assessment – comprehensive liver function testing, imaging, and 99mTc‑MAA lung shunt scan to tailor Y‑90 dose.
• Selective Y‑90 dosing – use personalized dosimetry (e.g., partition model) to keep healthy liver dose <30–35 Gy, as recommended by the Society of Interventional Radiology.<sup>[4]</sup>
• Optimize baseline liver health – treat viral hepatitis, encourage weight loss in NASH, manage diabetes, and advise alcohol cessation before embolization.
• Staged treatment – in patients with large tumor burden, consider splitting Y‑90 into two sessions to reduce per‑session radiation.
• Post‑procedure monitoring – early labs (within 48 h) to detect rapid enzyme rise; intervene promptly.

Complications

If radiation hepatitis is not recognized or adequately managed, several serious complications may develop:

• Acute liver failure (ALF) – rapid loss of synthetic function, encephalopathy, coagulopathy; mortality 40‑70 % without transplantation.
• Portal hypertension – leading to variceal bleeding, refractory ascites.
• Cholestatic liver injury – prolonged bilirubin elevation, pruritus, and risk of bile‑duct strictures.
• Secondary infections – bacterial peritonitis or spontaneous bacterial peritonitis (SBP) in ascitic patients.
• Exacerbation of underlying cirrhosis – accelerating decompensation and reducing transplant eligibility.
• Delayed tumor progression – if liver dysfunction precludes further oncologic therapies.

When to Seek Emergency Care

---

References

1. Salem R, et al. “Radioembolization with Yttrium‑90 microspheres for liver malignancies: Safety and efficacy.” J Vasc Interv Radiol. 2022;33(5):813‑823.
2. Köhler G, et al. “Incidence of radiation‑induced hepatitis after selective internal radiation therapy.” Radiology. 2021;299(2):401‑410.
3. Siddiqui S, et al. “Corticosteroid use in radiation‑induced liver injury: A systematic review.” Hepatology. 2020;71(4):1245‑1254.
4. Society of Interventional Radiology (SIR). “Guidelines for Y‑90 Dosimetry and Patient Selection.” 2023.

```